INT189580

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.49
First Reported 2006
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 9
Total Number 9
Disease Relevance 5.90
Pain Relevance 0.05

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (KDR) cytoplasmic membrane-bounded vesicle (KDR) plasma membrane (KDR)
nucleus (KDR) cytoplasm (KDR)
Anatomy Link Frequency
bone marrow 8
KDR (Homo sapiens)
KDR - V297I (1)
Pain Link Frequency Relevance Heat
cytokine 14 99.02 Very High Very High Very High
Inflammation 5 43.00 Quite Low
dysesthesia 1 42.68 Quite Low
palliative 6 38.76 Quite Low
imagery 2 38.56 Quite Low
ischemia 2 31.52 Quite Low
corticosteroid 2 22.68 Low Low
dexamethasone 29 5.00 Very Low Very Low Very Low
fibrosis 9 5.00 Very Low Very Low Very Low
cva 7 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Leukemia 72 99.64 Very High Very High Very High
Pancreatic Cancer 69 99.64 Very High Very High Very High
Hypoxia 20 98.76 Very High Very High Very High
Cancer 109 97.90 Very High Very High Very High
Hematologic Neoplasms 14 96.48 Very High Very High Very High
Solid Tumor 35 94.72 High High
Recurrence 5 82.64 Quite High
Hypertension 83 82.24 Quite High
Toxicity 38 80.80 Quite High
Hypersensitivity 11 77.20 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
CD34+, or CD45brightCD34+ cells were quantified for KDR expression.
Positive_regulation (quantified) of Gene_expression (expression) of KDR
1) Confidence 0.49 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2972200 Disease Relevance 0.15 Pain Relevance 0
HEK293 s cells that were transfected with VEGFR2 V297I SNP had significantly low VEGF binding efficiency regardless of VEGFR2 H472Q genotype, while variant VEGFR2 H472Q allele had minimal effect on VEGF binding efficiency [10].
Positive_regulation (transfected) of Gene_expression (transfected) of VEGFR2 (V297I)
2) Confidence 0.49 Published 2010 Journal J Exp Clin Cancer Res Section Body Doc Link PMC2913951 Disease Relevance 0.55 Pain Relevance 0
"Angiogenesis switch" in leukemia is documented by increased bone marrow MVD, increased expression of HIF-1, multiple pro-angiogenic factors (VEGF, bFGF, angiopoietin-2), soluble VEGFR, and decreased expression of endogenous angiogenesis inhibitors, such as thrombospondin-1 [50,51].
Positive_regulation (increased) of Gene_expression (expression) of VEGFR in bone marrow associated with leukemia
3) Confidence 0.36 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2902424 Disease Relevance 1.52 Pain Relevance 0
Another interesting finding was that AM-hMSCs expressed CD34 and showed increased expression of FLT-1 and KDR when cultured in the presence of VEGF: such expression, which recapitulates the basic phenotypic profile of circulating Endothelial Progenitor Cells (EPCs), is further evidence that AM-hMSCs have an angiogenic potential; the fact that, under the same culture conditions, AM-hMSCs did not express the CD133 surface molecule helps to distinguish these cells from the bone marrow-derived progenitors [41] (data not shown).
Positive_regulation (increased) of Gene_expression (expression) of KDR in bone marrow
4) Confidence 0.35 Published 2007 Journal BMC Dev Biol Section Body Doc Link PMC1810523 Disease Relevance 0.08 Pain Relevance 0
“Angiogenesis switch” in leukemia is documented by increased bone marrow MVD (Figures 2(a) and 2(b)), increased expression of HIF-1, multiple proangiogenic factors (VEGF, bFGF, angiopoietin-2), soluble VEGFR, and decreased expression of endogenous angiogenesis inhibitors, such as thrombospondin-1 [11, 12].
Positive_regulation (increased) of Gene_expression (expression) of VEGFR in bone marrow associated with leukemia
5) Confidence 0.35 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2875768 Disease Relevance 1.05 Pain Relevance 0
Oncogene/tumor suppressor gene activation, tissue hypoxia and cytokine secretion by pancreatic cancer cells results in increased expression of VEGF and VEGFR (Cherrington et al 2000; Baker et al 2001; Dvorak 2002).
Positive_regulation (increased) of Gene_expression (expression) of VEGFR associated with hypoxia, cancer, pancreatic cancer and cytokine
6) Confidence 0.26 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727890 Disease Relevance 0.75 Pain Relevance 0.05
“Angiogenesis switch” in leukemia is documented by increased bone marrow MVD (Figures 2(a) and 2(b)), increased expression of HIF-1, multiple proangiogenic factors (VEGF, bFGF, angiopoietin-2), soluble VEGFR, and decreased expression of endogenous angiogenesis inhibitors, such as thrombospondin-1 [11, 12].
Positive_regulation (increased) of Gene_expression (expression) of VEGFR in bone marrow associated with leukemia
7) Confidence 0.25 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2875768 Disease Relevance 1.12 Pain Relevance 0
Confirming the endothelial differentiation of the cells, flow cytometry analysis revealed an increased expression of FLT-1, KDR, ICAM-1 and the appearance of CD34 when cells had been cultured with VEGF (Figure 8).
Positive_regulation (increased) of Gene_expression (expression) of KDR
8) Confidence 0.24 Published 2007 Journal BMC Dev Biol Section Body Doc Link PMC1810523 Disease Relevance 0.05 Pain Relevance 0
VEGF is expressed in plexiform lesions and its receptor VEGFR-2 and the HIF-1 transcription complex are overexpressed [80].
Positive_regulation (overexpressed) of Gene_expression (overexpressed) of VEGFR-2
9) Confidence 0.03 Published 2006 Journal Respir Res Section Body Doc Link PMC1351173 Disease Relevance 0.63 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox